Skip to main content

Table 1 The 2016 WHO classification of acute myeloid leukemia (AML) and related neoplasms

From: Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies

AML with recurrent genetic abnormalities
 AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
 AML with inv. (16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11
 APL with PML-RARA
 AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A
 AML with t(6;9)(p23;q34.1);DEK-NUP214
 AML with inv. (3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
 AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1
 Provisional entity: AML with BCR-ABL1
 AML with mutated NPM1
 AML with biallelic mutations of CEBPA
 Provisional entity: AML with mutated RUNX1
AML with myelodysplasia-related changes
Therapy-related myeloid neoplasms
AML, NOS
 AML with minimal differentiation
 AML without maturation
 AML with maturation
 Acute myelomonocytic leukemia
 Acute monoblastic/monocytic leukemia
 Pure erythroid leukemia
 Acute megakaryoblastic leukemia
 Acute basophilic leukemia
 Acute panmyelosis with myelofibrosis
Myeloid sarcoma
Myeloid proliferations related to Down syndrome
 Transient abnormal myelopoiesis (TAM)
 Myeloid leukemia associated with Down syndrome
  1. APL, acute promyelocytic leukemia; NOS, not otherwise specified